Russia National vs EAEU Registration: Choosing the Right Pathway

1. Key takeaways

As of the latest verification date, there are two parallel pathways into the Russian market: national registration under Russian rules (Government Resolution No. 1684, which yields a national registration certificate, RU) and Eurasian Economic Union registration (EEC Decision No. 46, which yields a Union registration certificate valid across 5 member states). The decision ultimately rests on only three variables: the number of target markets, the maturity of your evidence package, and whether you can submit a national-rules application before December 31, 2027. For single-purpose products aimed only at the Russian market, the national pathway remains fully open.

The practical significance of this framework is that neither pathway is universally superior. The national route offers procedural predictability within one jurisdiction, while the Union route multiplies market coverage in a single procedure. The correct choice depends on portfolio strategy, timing constraints imposed by the transition window, and how much of the technical evidence required under Union rules already exists in a reusable form. Manufacturers who map these variables early avoid costly late-stage rework.

A useful way to frame the comparison is to distinguish what each pathway optimizes. The national pathway optimizes certainty: one authority, one set of forms, statutory durations expressed in working days, and a register the local team already knows how to work with. The Union pathway optimizes reach: a single expert review, one certificate, and circulation across five member states under one legal framework, at the cost of a heavier evidentiary package and a recognition stage whose duration is partly outside the applicant’s control. Because the decision variables interact, the answer for a given product can legitimately change over time: a device filed nationally in 2026 may still need a Union application in 2028 for a line extension. Treating the choice as a repeatable assessment rather than a one-off judgment keeps the portfolio coherent as the transition deadline approaches.

2. Legal basis

The following instruments jointly define the dual-track framework for placing medical devices on the Russian market. Each entry lists the act, its reference number, its date, and the specific provisions relevant to pathway selection.

3. Expert insights

Insight one: the window is defined by the submission date, not the certificate date. The protocol constrains the point in time at which an application must be submitted. Considering that under Resolution No. 1684 the statutory procedure takes 31 working days for devices that do not require human clinical trials and 50 working days for those that do — in both cases excluding trials and deficiency-response time — the practical estimate is that dossier preparation and clinical arrangements must begin several months before the intended submission. Waiting until mid-2027 to start preparation is a high-risk plan, because any deficiency round or trial delay will push the submission past the closing date with no possibility of recovery under national rules.

Insight two: the value of the Union pathway scales with the number of member states. One Union registration covers Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan — 5 markets in a single procedure. If the commercial plan covers only Russia, the national pathway offers higher procedural certainty within a familiar single-authority environment. If sales are planned in more than 2 member states, the marginal cost advantage of the Union pathway becomes obvious, since one dossier, one expert review and one certificate replace several national procedures. The trade-off is a heavier evidentiary burden upfront.

Insight three: post-market obligations differ between the two pathways. Order No. 540н expressly excludes devices registered under Union law from its scope; those devices follow Union post-market surveillance rules under Decision No. 174. Devices holding national registration certificates remain subject to Order No. 540н. Manufacturers with a mixed portfolio must confirm the applicable rules certificate by certificate — one generic SOP cannot serve both regimes, because surveillance formats, reporting channels and competent authorities differ.

Two pitfalls recur in pathway selection discussions. The first is deciding by cost alone: Union registration looks cheaper per market when five markets are counted, but the comparison collapses if the evidence package must be rebuilt to Union depth, because testing, QMS documentation and clinical justification carry real preparation cost. The second is deciding by imitation: a pathway that suited a competitor’s portfolio may be wrong for yours, since competitor timelines, market priorities and evidence positions differ. The disciplined approach is to score each registration unit against the three decision variables — market coverage, evidence maturity and submission feasibility within the window — and to record the scoring so that the rationale survives personnel changes and future audits. In a regulated environment, a decision that cannot be re-derived from its documented inputs is itself a liability.

4. Practical recommendations

1. Calculate market coverage and the target certificate date before calculating cost: if the product serves only Russia and the evidence is not yet ready, prioritize the national pathway; if multiple countries are targeted and the evidence is mature, go directly to the Union pathway. Run this assessment per registration unit rather than per company, because conclusions will legitimately differ across the portfolio.
2. For clients planning new product launches after 2028, start preparing testing and QMS materials to Union-rules depth now. Retrospective conversion of national-style dossiers into Union-format documentation is slower and more expensive than building it correctly from the outset.
3. Manufacturers with mixed portfolios should build a certificate-to-applicable-rules mapping table and use it as an input to the post-market system design. Review the mapping whenever a new certificate is issued, a renewal or change is processed, or the underlying legal acts are amended.

5. Verification checklist

• □ The number of member states covered by each product line has been defined
• □ The expected submission date of each national-pathway application is confirmed to fall before December 31, 2027
• □ The project schedule has been back-planned from the statutory durations (31 working days / 50 working days)
• □ Mixed portfolios have completed the certificate-to-post-market-rules mapping
• □ Evidence gaps for post-2028 products under the Union pathway have been assessed

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers entering the Russian market with end-to-end regulatory services covering both registration pathways: national registration under ПП РФ No. 1684, including route selection among clauses 63, 87 and 101, and EAEU registration under ЕЭК Decision No. 46, together with classification strategy support under Decision No. 173 as amended. Our team helps define the optimal route for each registration unit, prepare dossiers and testing plans, coordinate with RZN and expert institutions, and track transition deadlines through December 31, 2027. For tailored support on Russia market entry, pathway selection and dossier preparation, contact GRZAN at info@grzanglobal.com.